Scholars Central

Conference abstractPublished 3 Sep 2018

A multi-institutional, randomized, double-blinded, placebo-controlled trial of additive Duloxetine for cancerrelated neuropathic pain refractory to opioids and gabapentinoids: JORTC PAL-08 (DIRECT study)

Authors: Hiromichi Matsuoka

University of Technology Sydney, AustraliaKindai University, Japan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction & Aim: Management of cancer-related neuropathic pain refractory to opioids remains challenging. We have investigated the additional efficacy of duloxetine for cancer-related neuropathic pain refractory to opioids and gabapentinoids. Method: A multicenter, randomized, double-blind, placebo-controlled trial. Patients with any cancer-related neuropathic pain, currently taking opioids, non-responsive or intolerant to gabapentinoids were eligible. Diagnosis of neuropathic pain was based on the International Association for the Study of Pain (IASP) algorithm. Patients with chemotherapy-induced peripheral neuropathies were excluded. Patients were administrated 20 mg to 40 mg of duloxetine or placebo for 10 days. The primary endpoint was the average pain intensity (Brief Pain Inventory (BPI) item 5 at day 10 (BPI d10). Result: 70 patients were enrolled at 12 sites. BPI on day 0 (before treatment) were 5.6 in group D (duloxetine) and 5.7 in group P (placebo). BPId 10 was: (1) Average of group D 4.03 [90% CI 3.33, 4.74], group P 4.88 [4.37, 5.38] (P=.053) (Complete Case: CC analysis) and (2) Group D 4.06 [3.37, 4.74], group P 4.91 [4.41, 5.41] (P=0.048) (Baseline Observation Carried Forward: BOCF analysis). Point estimate of the difference of average values between the two groups was -0.84 [-1.71, 0.02] (CC analysis) and -0.85 [-1.69, -0.01] (BOCF analysis). Compared to day 0, the improvement rate of 30% or more and 50% or more at day 10, were 44.1% in group D, 18.2% in group P (P=0.022) and 32.4% in group D, 3.0% in group P (P=0.002), respectively. Although there was one case of discontinuation of adverse events in Grade 3 (CTCAE version 4, JCOG), it was due to deterioration of the primary disease and there was no relation with protocol treatment. Conclusion: Duloxetine is clinically effective for cancer-related neuropathic pain.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Palliative Care & Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Palliative Care & Medicine
  • SubjectAlternative & Palliative Care
  • BylineArticles whose byline prints “Hiromichi Matsuoka”